Head-to-head · Cost-Efficiency Index
Invyncible vs Layla
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Invyncible
Cost-first shoppers who want compounded GLP-1 combo programs (with B12/glycine) alongside brand Wegovy/Zepbound on one platform.
Visit InvyncibleLayla
Cost-first shoppers who want brand-name GLP-1 access from shoppers who don't need a compounded/lower-cost option.
Visit LaylaThe verdict
Invyncible and Layla tie on the Cost-Efficiency Index at 59/100, so neither wins outright on the numbers. For most shoppers we'd start with Invyncible (ranked #272, a hair above #274) — Cost-first shoppers who want compounded GLP-1 combo programs (with B12/glycine) alongside brand Wegovy/Zepbound on one platform. But Layla is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Invyncible.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Invyncible | Layla |
|---|---|---|
| Cost-Efficiency Index | 59/100 | 59/100 |
| Semaglutide / mo | $149/mo (0.45 mg dose, compounded with glycine + B12) | $1,399/mo (brand Ozempic, promotional rate) |
| Tirzepatide / mo | $180/mo (2.5 mg weekly, 4-week program, compounded) | $1,399/mo (brand Mounjaro, promotional rate) |
| Semaglutide / yr (modeled) | $1,788 | $16,788 |
| Tirzepatide / yr (modeled) | $2,160 | $16,788 |
| Coverage | 46 states plus DC | Coverage not published |
| Oral / sublingual | Yes | Yes |
| Brand-name access | Yes | Yes |
| Rank here | #272 | #274 |
Invyncible
59/100Where the value is
- Publishes real itemized dollar prices for eight separate combo programs plus two brand options directly on the site, no signup required, with the mg vial size named in every dose option
- Sells FDA-approved brand Wegovy ($1,750/mo) and Zepbound ($1,540/mo) alongside compounded options
- Names all six compounding pharmacies with street addresses and phone numbers and lets the patient choose which one fills the prescription
The tradeoffs
- Every listed price is shown as a discount off a much higher struck-through 'list' price, and the page invites further negotiation — reads as permanent anchor pricing
- The entry figure is the smallest vial: plain compounded semaglutide runs $192.50, $262.50 and $350 across its three vial sizes, and the FAQ confirms cost rises with dose
Layla
59/100Where the value is
- All-inclusive pricing bundles health check-ins, telehealth visits, prescription and unlimited doctor messaging into one price
- Named Medical Director (Dr. Ruth Cohen) disclosed on-site
- LegitScript-certified badge displayed; fast 2-3 day shipping claimed
The tradeoffs
- Brand-only and expensive: the real floor is $1,399/mo (Ozempic/Mounjaro), not the $1,299 the homepage FAQ separately claims — the two figures don't reconcile
- The lowest Zepbound figure shown ($1,599) is a one-time new-customer discount off a $1,699 standing price, not an ongoing rate
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.